FIELD: medicine.
SUBSTANCE: invention relates to medicine, namely to cardiac surgery, and represents cardioplegic solution, which contains sodium chloride - 3.41-3.62, potassium chloride - 1.092-1.156 g, magnesium chloride - 3.190-3.485 g, calcium gluconate - 0.0105-0.0130 g, mannite - 4.365-4.520 g, L-carnosine - 20.1504-24.1650 g, N-acetylcarnosine - 8.056-11.032 g, L-histidine - 0.705-0.820 g, water for injections to 1000 ml.
EFFECT: invention ensures prevention of reduction of amplitude, speed of front and speed of pulse-wave reduction, as well as increase of diastolic pressure in left heart ventricle during reperfusion with preservation of buffer capacity and osmolarity of cardioplegic solution with physiological pH parameters.
4 tbl, 2 ex
Title | Year | Author | Number |
---|---|---|---|
ASN-BOKERIYA-BOLDYREV CARDIOPLEGIC SOLUTION | 2009 |
|
RU2413502C1 |
CRYSTALLOID CARDIOPLEGIC SOLUTION | 2009 |
|
RU2423135C2 |
CARDIOPLEGIA AGENT (VERSIONS) | 2014 |
|
RU2568911C1 |
CRYSTALLOID CARDIOPLEGIC SOLUTIONS, CONTAINING DODECAPEPTIDES (VERSIONS) | 2013 |
|
RU2549470C1 |
"INFUSOL" CARDIOPLEGIC SOLUTION | 2002 |
|
RU2226093C1 |
METHOD OF HEARTBEAT RECOVERY FOLLOWING DIASTOLIC ARREST IN EXPERIMENT | 2010 |
|
RU2424582C1 |
SOLUTION FOR CONSERVATION OF LIVE ORGANS | 1992 |
|
RU2025973C1 |
METHOD FOR PROTECTING HEART FROM ISCHEMIA UNDER EXPERIMENTAL CONDITIONS | 1996 |
|
RU2144825C1 |
METHOD FOR EVALUATING THE STATE OF MYOCARDIUM IN CARDIOSURGICAL INTERVENTIONS UNDER CONDITIONS OF CARDIOPLEGIC PROTECTION | 2017 |
|
RU2651364C1 |
METHOD FOR CARDIOPLEGIC ARREST (VERSIONS) | 2015 |
|
RU2571058C1 |
Authors
Dates
2015-04-20—Published
2013-09-11—Filed